| Title |
Managing Suicide Risk in Patients with Schizophrenia
|
|---|---|
| Published in |
CNS Drugs, August 2012
|
| DOI | 10.2165/11586450-000000000-00000 |
| Pubmed ID | |
| Authors |
John Kasckow, Kandi Felmet, Sidney Zisook |
| Abstract |
The management of suicide risk in patients with schizophrenia poses many challenges for clinicians. Compared with the general population, these patients have an 8.5-fold greater risk of suicide. This article reviews the literature dealing with the treatment of at-risk patients with schizophrenia. An integrated psychosocial and pharmacological approach to managing this population of patients is recommended. Although there is at least modest evidence suggesting that antipsychotic medications protect against suicidal risk, the evidence appears to be most favourable for second-generation antipsychotics, particularly clozapine, which is the only medication approved by the US FDA for preventing suicide in patients with schizophrenia. In addition, treating depressive symptoms in patients with schizophrenia is an important component of suicide risk reduction. While selective serotonin receptor inhibitors (SSRIs) ameliorate depressive symptoms in patients with schizophrenia, they also appear to attenuate suicidal thoughts. Further research is needed to more effectively personalize the treatment of suicidal thoughts and behaviours and the prevention of suicide in patients with schizophrenia. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 1 | 50% |
| Members of the public | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 133 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Chile | 1 | <1% |
| Uruguay | 1 | <1% |
| India | 1 | <1% |
| Japan | 1 | <1% |
| United States | 1 | <1% |
| Unknown | 128 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 21 | 16% |
| Student > Master | 21 | 16% |
| Student > Postgraduate | 14 | 11% |
| Student > Bachelor | 11 | 8% |
| Other | 11 | 8% |
| Other | 27 | 20% |
| Unknown | 28 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 42 | 32% |
| Psychology | 22 | 17% |
| Nursing and Health Professions | 10 | 8% |
| Agricultural and Biological Sciences | 7 | 5% |
| Neuroscience | 7 | 5% |
| Other | 12 | 9% |
| Unknown | 33 | 25% |
Attention Score in Context
This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 May 2019.
All research outputs
#4,190,491
of 25,371,288 outputs
Outputs from CNS Drugs
#392
of 1,387 outputs
Outputs of similar age
#29,527
of 187,944 outputs
Outputs of similar age from CNS Drugs
#130
of 541 outputs
Altmetric has tracked 25,371,288 research outputs across all sources so far. Compared to these this one has done well and is in the 83rd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,387 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.6. This one has gotten more attention than average, scoring higher than 71% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 187,944 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 84% of its contemporaries.
We're also able to compare this research output to 541 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 75% of its contemporaries.